胰高血糖素样肽1受体激动剂与甲状腺肿瘤风险:一项回顾性队列研究
该回顾性、活性对照、新用户队列研究利用国际行政索赔和电子健康记录数据库,纳入接受过二甲双胍治疗的2型糖尿病患者,比较启动胰高血糖素样肽1受体激动剂(GLP-1RA)与启动钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)、二肽基肽酶4抑制剂(DPP-4i)和磺脲类(SU)的患者,发现GLP-1RA暴露与甲状腺肿瘤风险增加无关。
要点
- GLP-1RA与SGLT2i、SU或DPP-4i相比,甲状腺肿瘤风险均无显著增加。
- GLP-1RA队列甲状腺肿瘤发病率为0.88至1.03/1000人年。
- 使用甲状腺恶性肿瘤及1年滞后期的分析结论相似。
核心结论
- 在启动二线治疗的2型糖尿病患者中,观察到GLP-1RA暴露与甲状腺肿瘤风险增加无关。
研究设计与样本
- 回顾性、活性对照、新用户队列研究,使用国际行政索赔和电子健康记录数据库。
- 纳入既往接受二甲双胍治疗的2型糖尿病患者,比较启动GLP-1RA与新使用SGLT2i、DPP-4i和SU的患者。
- 采用倾向评分匹配和分层调整混杂因素,分析策略为意向性治疗和接受治疗。
- 使用Cox回归估计风险比(HR),并通过随机效应Meta分析合并。
- 使用阴性结局评估未测量混杂,并对HR进行校准。
主要发现
- 共纳入460,032名GLP-1RA使用者、717,792名SGLT2i使用者、2,055,583名DPP-4i使用者和1,119,868名SU使用者。
- 仅美国队列通过研究诊断性检验。
- GLP-1RA队列甲状腺肿瘤发病率为0.88至1.03/1000人年。
- Meta分析:GLP-1RA vs SGLT2i的HR范围为0.83(95%CI 0.57-1.27)至0.95(0.85-1.06)。
- Meta分析:GLP-1RA vs SU的HR范围为0.95(95%CI 0.75-1.20)至1.03(0.87-1.23)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and risk of incident thyroid tumors. RESEARCH DESIGN AND METHODS: The retrospective, active-comparator new-user cohort study used international administrative claims and electronic health record databases. Participants included patients with type 2 diabetes mellitus (T2DM) with prior metformin therapy initiating a GLP-1RA versus new users of sodium-glucose cotransporter 2 inhibitors (SGLT2is), dipeptidyl peptidase 4 inhibitors (DPP-4is), and sulfonylureas (SUs). The outcome was incident thyroid tumor and thyroid malignancy. Propensity score matching and stratification were used to adjust for confounders with an intention-to-treat and on-treatment strategy. Cox regression was used to estimate hazard ratios (HRs) pooled using a random-effects meta-analysis. Unmeasured confounding was evaluated using negative outcomes, with calibration of the HR. RESULTS: A total of 460,032 users of GLP-1RAs, 717,792 users of SGLT2is, 2,055,583 users of DPP-4is, and 1,119,868 users of SUs were included. Only U.S. cohorts passed study diagnostics. Thyroid tumor incidence ranged from 0.88 to 1.03 per 1,000 person-years in GLP-1RA cohorts. GLP-1RA exposure was not associated with an increased risk of thyroid tumors compared with SGLT2is, DPP-4is, or SUs (meta-analysis: GLP-1RA vs. SGLT2i HR range from 0.83 [95% CI 0.57-1.27] to 0.95 [0.85-1.06]; GLP-1RA vs. SU HR range from 0.95 [0.75-1.20] to 1.03 [0.87-1.23]; GLP-1RA vs. DPP-4i HR range from 0.78 [0.60-1.01] to 0.93 [0.83-1.04]). Analysis using thyroid malignancy and including a 1-year lag period produced similar conclusions. CONCLUSIONS: In patients with T2DM initiating second-line treatments, we observed no increased risk of thyroid tumors with GLP-1RA exposure.
引用
- Morales DR, Bu F, Viernes B, et al. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025. PMID: 40465422. doi:10.2337/dc25-0154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。